Mississippi’s bold attempt to tackle its obesity crisis with Medicaid-covered weight loss drugs has raised a provocative question: Why are so few people getting the medicine that could change their lives?
Story Snapshot
Mississippi Medicaid approved coverage for GLP-1 weight loss drugs in 2023, but uptake is shockingly low.
Only 2% of eligible adults have received prescriptions, despite the state’s sky-high obesity rate.
Barriers include drug shortages, complex red tape, and a lack of awareness among both doctors and patients.
The disconnect exposes deeper systemic challenges that could shape the future of obesity care nationwide.
Coverage Expansion Collides With Reality
Mississippi joined a small club in 2023 by extending Medicaid coverage to GLP-1 medications—like Wegovy and Saxenda—for obesity. The move was lauded as a potential game-changer for a state where nearly 40% of adults are obese and the health effects ripple through families and communities. Yet by December 2024, only about 2% of eligible adults on Medicaid had actually received a prescription. For a policy designed to reach tens of thousands, the numbers are astonishingly small.
In Mississippi, Medicaid Coverage of Weight Loss Drugs Fails To Catch On – KFF Health News https://t.co/D2s7EgqDbu
— Neil Floch MD (@NeilFlochMD) October 16, 2025
Obstacles Thwarting Patients and Providers
Multiple barriers have held back what was supposed to be a transformative benefit. First, a national shortage of GLP-1 drugs meant pharmacies often couldn’t fill prescriptions, leaving patients in limbo. Second, strict prior authorization requirements—intended to manage costs and ensure appropriate use—created a paperwork maze for doctors. Many providers, already overburdened and skeptical, avoided the extra hassle.
Even when the medication was technically available, few patients knew to ask for it. Meanwhile, the Medicaid Drug Utilization Review Board reviewed the paltry numbers while pressure mounted to justify the millions spent. The cycle of low awareness, administrative friction, and ongoing shortages fed on itself and stymied progress.
The Weight of Expectations
Mississippi Medicaid officials set the rules and track the spending, but the power to actually prescribe and access these drugs rests with front-line providers and patients. In the background, patient advocacy groups and policymakers watch closely. The state’s experience could set a precedent for the rest of the country. If one of the nation’s most at-risk populations can’t make use of a supposedly groundbreaking benefit, what hope is there for other states wrestling with the costs and complexities of obesity care? The pressure is on Medicaid to show not just good intentions, but real impact.
Missed Opportunities and Unanswered Questions
The stakes are high. Mississippi’s $12 million investment so far has delivered little in the way of improved health or reduced hospitalizations. The most vulnerable—residents of the Mississippi Delta—are still missing out. If barriers persist, the short-term effect is wasted resources and deepening health disparities. If uptake improves, there’s potential for better outcomes and cost savings as obesity rates, diabetes, and heart disease decline.
The story is not just about numbers but about the human cost of policy inertia and systemic gaps. The open question: Will Mississippi crack the code, or will its Medicaid experiment become another cautionary tale in America’s struggle with obesity?
Sources:
KFF Health News
KFF.org Medicaid Coverage Analysis
GoodRx Medicaid Coverage Guide
Mississippi Division of Medicaid Policy Documents
Mississippi Division of Medicaid Preferred Drug List
